BACKGROUND: Malaria continues to be a serious, world-wide infection. Atovaquone-proguanil is one of the prophylactic agents recommended for travelers to endemic regions. However, little information is available regarding adherence with this medication. A large proportion of malaria cases reported from travelers is due to non-adherence to prescribed regimens. This study was undertaken to analyze adherence with atovaquone-proguanil prophylaxis and specific factors contributing to non-adherence. METHODS: Men and non-pregnant women > or = 18 years of age were eligible for inclusion. Enrolled travelers received a prescription for atovaquone-proguanil prophylaxis and were contacted by telephone within 3 weeks of return to the United States. A questionnaire was prepared by the authors to determine if subjects were adherent with the medication. Additional data included demographics, duration of malarious travel, previous use of prophylactic agents, underlying medical conditions, concurrent medications, and reasons for non-adherence. RESULTS: Complete data were available for 104/124 (84%) participants: 49 (47%) men, 55 (53%) women. Average duration of malarious travel was 12 days, and 19 (18%) travelers reported previous travel to a malarious region. Ninety-two (89%) subjects were completely adherent with their prophylactic atovaquone-proguanil course. Adverse effects were seen in 6 (5%) travelers. CONCLUSIONS: Adherence with atovaquone-proguanil malaria prophylaxis is high among travelers from a non-endemic region. Adverse effects are minimal. Non-adherence was primarily attributable to travelers' perception of need.
BACKGROUND:Malaria continues to be a serious, world-wide infection. Atovaquone-proguanil is one of the prophylactic agents recommended for travelers to endemic regions. However, little information is available regarding adherence with this medication. A large proportion of malaria cases reported from travelers is due to non-adherence to prescribed regimens. This study was undertaken to analyze adherence with atovaquone-proguanil prophylaxis and specific factors contributing to non-adherence. METHODS:Men and non-pregnant women > or = 18 years of age were eligible for inclusion. Enrolled travelers received a prescription for atovaquone-proguanil prophylaxis and were contacted by telephone within 3 weeks of return to the United States. A questionnaire was prepared by the authors to determine if subjects were adherent with the medication. Additional data included demographics, duration of malarious travel, previous use of prophylactic agents, underlying medical conditions, concurrent medications, and reasons for non-adherence. RESULTS: Complete data were available for 104/124 (84%) participants: 49 (47%) men, 55 (53%) women. Average duration of malarious travel was 12 days, and 19 (18%) travelers reported previous travel to a malarious region. Ninety-two (89%) subjects were completely adherent with their prophylactic atovaquone-proguanil course. Adverse effects were seen in 6 (5%) travelers. CONCLUSIONS: Adherence with atovaquone-proguanilmalaria prophylaxis is high among travelers from a non-endemic region. Adverse effects are minimal. Non-adherence was primarily attributable to travelers' perception of need.
Authors: Rhett J Stoney; Lin H Chen; Emily S Jentes; Mary E Wilson; Pauline V Han; Christine M Benoit; William B MacLeod; Davidson H Hamer; Elizabeth D Barnett Journal: Am J Trop Med Hyg Date: 2015-10-19 Impact factor: 2.345
Authors: Klaske Vliegenthart-Jongbloed; Mariana de Mendonça Melo; Marlies E van Wolfswinkel; Rob Koelewijn; Jaap J van Hellemond; Perry J J van Genderen Journal: Malar J Date: 2013-07-31 Impact factor: 2.979
Authors: Abdoulkader Ali Adou; Francesco Napolitano; Alessandra Vastola; Italo Francesco Angelillo Journal: PLoS One Date: 2019-04-12 Impact factor: 3.240
Authors: Sanne-Meike Belderok; Anneke van den Hoek; Will Roeffen; Robert Sauerwein; Gerard J B Sonder Journal: PLoS One Date: 2013-02-25 Impact factor: 3.240